Daytrana Post-Marketing Study Of Skin Sensitization Urged By Committee
Executive Summary
Post-marketing surveillance and study of skin sensitization with Shire/Noven's Daytrana methylphenidate patch for attention deficit/hyperactivity disorder were recommended by FDA's Psychopharmacologic Drugs Advisory Committee at its Dec. 2 meeting
You may also be interested in...
Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval
Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling
Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval
Wholesalers Drawing DoJ Scrutiny In Drug Diversion Investigations
Wholesalers will face increasing Justice Department scrutiny in pharmaceutical diversion cases, a federal prosecutor predicted